Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single-dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Quizartinib in Subjects With Moderate Impaired Hepatic Function as Defined by NCI-ODWG Criteria

NCT04473664 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT04473664
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04473664 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single-dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Quizartinib in Subjects With Moderate Impaired Hepatic Function as Defined by NCI-ODWG Criteria
Lead sponsor
Daiichi Sankyo
Phase
Phase 1
Overall status
Completed
Start date
September 22, 2020
Completion date
July 22, 2021
Enrollment
12 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic impairment, moderate impaired hepatic function